Table 1.
Baseline characteristics of patients from bimekizumab (BE OPTIMAL/BE COMPLETE/BE VITAL) and risankizumab (KEEPsAKE-1/2) trials before matching
| Mean (SD) unless stated | bDMARD naïve | TNFi-IR | ||
|---|---|---|---|---|
| BE OPTIMAL | KEEPsAKE-1 | BE COMPLETE/BE VITAL | KEEPsAKE-2 | |
| N = 431 | N = 483 | N = 267 | N = 106 | |
| Age, years | 48.5 (12.6) | 52—median value | 50.1 (12.4) | 54.2 (12.7) |
| Male, % | 47 | 52 | 49 | 44 |
| Time since diagnosis, years | 6.0 (7.3) | 7.1 (7.0) | 9.6 (9.9) | 10.5 (9.2) |
| MTX use, % | 59 | 65 | 45 | 45 |
| SJC (of 66 joints) | 9.0 (6.2) | 12.1 (7.8) | 9.7 (7.5) | 13.4 (8.9) |
| TJC (of 68 joints) | 16.8 (11.8) | 20.8 (14.1) | 18.4 (13.5) | 22.8 (14.9) |
| HAQ-DI score | 0.82 (0.59) | 1.15 (0.66) | 0.97 (0.59) | 1.20 (0.60) |
| BSA ≥ 3%, % | 50 | 57 | 66 | 55 |
bDMARD biologic disease-modifying anti-rheumatic drug, BSA body surface area, HAQ-DI Health Assessment Questionnaire–Disability Index, MTX methotrexate, SD standard deviation, SJC swollen joint count, TJC tender joint count, TNFi-IR tumor necrosis factor inhibitor-inadequate response or intolerant